Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5826735 | European Journal of Pharmacology | 2016 | 37 Pages |
Abstract
Type 2 diabetes mellitus is a risk factor for Alzheimer's disease (AD). The glucagon-like peptide-1 analog liraglutide, a novel long-lasting incretin hormone, has been used to treat type 2 diabetes mellitus. In addition, liraglutide has been shown to be neurotrophic and neuroprotective. Here, we investigated the effects of liraglutide on amyloid β protein (Aβ)-induced AD in mice and explored its mechanism of action. The results showed that subcutaneous administration of liraglutide (25nmol/day), once daily for 8 weeks, prevented memory impairments in the Y Maze and Morris Water Maze following Aβ1-42 intracerebroventricular injection, and alleviated the ultra-structural changes of pyramidal neurons and chemical synapses in the hippocampal CA1 region. Furthermore, liraglutide reduced Aβ1-42-induced tau phosphorylation via the protein kinase B and glycogen synthase kinase-3β pathways. Thus liraglutide may alleviate cognitive impairment in AD by at least decreasing the phosphorylation of tau.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Liqin Qi, Linfang Ke, Xiaohong Liu, Lianming Liao, Sujie Ke, Xiaoying Liu, Yanping Wang, Xiaowei Lin, Yu Zhou, Lijuan Wu, Zhou Chen, Libin Liu,